[Plant-derived terpenes in treating patients with urolithiasis]

Area of Science:

• Urology
• Pharmacology
• Nephrology

Background:

• Urolithiasis necessitates drug therapy for metabolic abnormalities.
• Plant-derived medications are crucial for treating and preventing urolithiasis.
• Extracorporeal shock wave lithotripsy (ESWL) is a common treatment for kidney stones.

Purpose of the Study:

• To evaluate the efficacy of Rowatinex in urolithiasis patients post-ESWL.
• To analyze blood and urine parameter changes with Rowatinex treatment.
• To assess Rowatinex's role in preventing recurrent stone formation.

Main Methods:

• Patients were divided into two groups post-ESWL.
• Group A (n=107) received Rowatinex.
• Group B (n=50) received antispasmodic drugs.

Main Results:

• 71.1% of patients receiving Rowatinex achieved stone fragment clearance within 1-5 days, compared to 40.4% in the control group.
• Rowatinex increased diuresis and stabilized urine pH (6.2-6.8), crucial for metaphylaxis.
• Leukocyturia decreased in both groups, with notable urine pH stabilization in the Rowatinex group.

Conclusions:

• Rowatinex enhances stone fragment clearance post-ESWL and reduces pain.
• It effectively reduces leukocyturia, increases diuresis, and stabilizes urine pH.
• Rowatinex is safe for long-term use and aids in preventing recurrent urolithiasis.